Millions of individuals suffer from chronic diseases that require continuous monitoring. Current monitoring applications tie them down to the clinic or home unit. Wearable diagnostic applications free individuals to live their lives. Clinical-grade monitoring offers peace of mind, while reliable data analytics provide medical practitioners with real-time results to make informed decisions.
Flexible and cost-effective, Nanowear delivers high-fidelity diagnostics and bridges the gap between protecting lives and freeing people to live them.
To be the world’s leading provider of nanosensor smart-textile technology by focusing on product development that not only enhances preventive health and well-being but also increases efficacy, efficiency and eliminates cost redundancies.
To improve the quality of preventive medicine, practitioner productivity, patient care and physical performance through nanotechnology-enabled diagnostic monitoring.
Nanowear is headquartered in New York City and its research and development facility is located in University Park, Pennsylvania.
Vice Chancellor and Director of Athletics, LSU
Chairman of EDventure Holdings
BCG Digital Ventures
Former CIO, Biogen and Novartis
SVP, Technology, First Data Corporation
Nicholas Sears M.D.
Former Chief Medical Officer, MedAssets
Robert Harbaugh M.D.
Distinguished Professor & Chairman of Neurosurgery, Penn State University
Yoaav Krauthammer M.D.
Electrophysiologist, HealthEast Care System
Mark Kronenfeld M.D.
Vice Chairman of Dept. of Anesthesiology, Maimonides Medical Center
David Theodoro M.D.
Cardiac Surgeon & Chairman, Cardiovascular Dept., SSM Heart Institute
January 5, 2018:
NEW YORK, NY – January 5, 2018 – Nanowear, the leader in cloth-based diagnostic monitoring nanosensor technology, today announced that it has entered into an exclusive, worldwide supply-chain partnership agreement with The Secant Group for scaled manufacturing and production of its medical-grade cloth-based nanosensor technology. Under the terms of the agreement, Nanowear and The Secant Group will have the collective obligation for marketing the technology and associated products. Click for full press release…
December 1, 2016:
NEW YORK, NY – December 1, 2016 – Nanowear, an early stage developer of cloth-based diagnostic monitoring nanosensor technology, today announced that it has received FDA Class II 510(k) clearance for its first product, SimplECG™, a remote cardiac monitoring undergarment. SimplECG™ collects continuous multi-channel ECG, heart rate and respiratory rate data from the garment and transfers it to a web-based portal for review by a physician, by way of a mobile application. The initial version of the product is iPhone-based. Click for full press release…
December 10, 2014:
NEW YORK, NY – December 10, 2014 – Nanowear, an emerging developer of wearable, textile-based diagnostic monitoring technology, today announced the appointment of leading medical and technology experts to its newly formed Advisory Board. The newly appointed Advisory Board will serve as a strategic resource to Nanowear as the Company continues product development and quality management in preparation for the U.S. Food and Drug Administration (FDA) approval process of its go-to-market product, a remote cardiac monitoring shirt for patients exhibiting symptoms of cardiovascular disease and potential ischemic events. Click for full press release…
September 10, 2014:
NEW YORK, NY – September 10, 2014 – Nanowear Inc., an early-stage developer of wearable, textile-based diagnostic monitoring technology, today announced a $1.5M seed investment led by The Social+Capital Partnership and MAS Holdings (Pvt.) Limited, with several influential angels also participating in the round. The seed investment will fund production scaling and continued testing / validation of the company’s go-to-market product, a remote cardiac monitoring wearable base layer, in preparation for the U.S. Food and Drug Administration’s (FDA) approval process. Click for full press release...
Contact us to learn more about how Nanowear can increase physician efficiency and patient experience while reducing the costs associated with diagnostic monitoring.
New York, NY (HQ) | University Park, PA (R&D)